Systemic sclerosis (scleroderma) is an autoimmune disease characterised by pathologic fibrosis of skin and internal organs (lungs, heart, kidneys), driven by activated fibroblasts that overproduce collagen and other extracellular matrix proteins.
Systemic sclerosis (scleroderma) is an autoimmune disease characterised by pathologic fibrosis of skin and internal organs (lungs, heart, kidneys), driven by activated fibroblasts that overproduce collagen and other extracellular matrix proteins. The underlying immunological dysfunction involves autoreactive T cells, B cells producing pathogenic antibodies (anti-topoisomerase, anti-centromere), and dysregulated cytokine signalling (TGF-β, IL-6). Placental MSCs are being explored as an anti-inflammatory and immunomodulatory intervention, delivering cytokines and cell-surface molecules that suppress autoreactive immune cells and potentially reprogram fibroblast behaviour. Unlike conventional disease-modifying antirheumatic drugs (DMARDs), cell therapy aims to reset immune tolerance rather than merely suppress inflammation. Note: autologous haematopoietic stem-cell transplantation (HSCT) is an established, though intensive, option for severe early-stage systemic sclerosis in selected candidates, with demonstrated benefit in some clinical series.
| 指示性成本 · 保加利亚 (EU) | €3,000–€8,000 |
|---|---|
| 全球市场成本范围 | €20,000–€27,500 (dvcstem.com) |
| 研究的主要细胞类型 | 羊膜膜中的间充质干细胞 |
| 批准状态 | 研究性 |
| 注册的临床试验 (ClinicalTrials.gov) | 42 · 7 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Forty-two completed trials and 7 currently recruiting trials are registered for systemic sclerosis, with diverse cell sources (placental MSC predominating, alongside autologous bone-marrow-derived MSC and HSCT). HSCT trials have shown arrest or reversal of skin fibrosis in approximately 70–80% of treated patients, with sustained benefit at 5-year follow-up in many, though the treatment carries significant morbidity (infection risk, infertility, relapse). MSC trials are smaller and earlier-stage; published data show stabilisation of skin thickening (modified Rodnan skin score stability or improvement) in 50–70% of placental MSC-treated participants over 6–24 months, often accompanied by improved lung function and hand mobility.
Depending on assessment, a Scleroderma (Systemic Sclerosis) protocol may draw on:
Placental MSC infusion for scleroderma costs €5,000–8,500 per treatment course, with many protocols involving two to three infusions spaced weeks to months apart. Autologous HSCT is substantially more expensive (€35,000–60,000), reflecting hospitalisation, high-dose chemotherapy conditioning, stem-cell mobilisation and reinfusion, and intensive post-transplant monitoring. Baseline assessments (skin biopsy, pulmonary function, cardiac imaging) add €2,000–3,500. Long-term immunosuppression post-HSCT incurs ongoing medication costs.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Scleroderma (Systemic Sclerosis) cost-by-country breakdown, or compare the best countries for Scleroderma (Systemic Sclerosis) →
Before booking, check safety & regulation, the recovery climate, 您是否可能是候选人, and which cell type fits Scleroderma (Systemic Sclerosis).
完整硬皮病（系统性硬化症）常见问题 → · 硬皮病（系统性硬化症）成本分解 →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: 我是候选人吗？ · 哪种细胞类型？ · Types of clinics & best countries · 成本计算器
由 StemCellAtlas 的编辑团队进行医学审查，与Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估